From: Alternate virtual populations elucidate the type I interferon signature predictive of the response to rituximab in rheumatoid arthritis
Therapy
Trial in MTX-IR patients
Rituximab, 1000 mg/kg, background MTX
[22]
Tocilizumab, 4 & 8 mg/kg, background MTX
LITHE [23], OPTION [24]
Anti-TNF (infliximab 3 & 10 mg/kg, adalimumab 40 mg/kg), background MTX
ATTRACT [6, 25], ATTEST [26]
